A5086574351- Estrogen and related hormone effects
- Retinoids in leukemia and cellular processes
- Global Cancer Incidence and Screening
- Antioxidant Activity and Oxidative Stress
- BRCA gene mutations in cancer
- Cancer Risks and Factors
- Biotin and Related Studies
- Growth Hormone and Insulin-like Growth Factors
- Skin Protection and Aging
- Advanced Breast Cancer Therapies
- Medical Imaging Techniques and Applications
- Neuroblastoma Research and Treatments
- Chronic Lymphocytic Leukemia Research
- Cancer, Lipids, and Metabolism
- Cancer survivorship and care
- Patient-Provider Communication in Healthcare
- Risk Perception and Management
- Disaster Management and Resilience
- Glioma Diagnosis and Treatment
- Physical Activity and Health
- Radiomics and Machine Learning in Medical Imaging
- Economic and Financial Impacts of Cancer
- Risk and Safety Analysis
- Breast Lesions and Carcinomas
- Cancer and Skin Lesions
The University of Texas MD Anderson Cancer Center
2015-2024
Johns Hopkins University
2017
Columbia University Irving Medical Center
2015
Physical activity (PA) is a known behavior to reduce cancer risk and improve survivorship, yet adherence PA guidelines poor among the general population survivors. The purpose of this study was determine extent which patients referred for exercise consultation within clinical prevention setting were meeting aerobic resistance physical identify factors associated with guideline adherence. Between 2013 2015, survivors interviewed by an physiologist Integrative Health Program at University...
Background: Breast cancer risk assessment including genetic testing can be used to classify people into different groups with screening and preventive interventions tailored the needs of each group, yet implementation risk-stratified breast prevention in primary care settings is complex. Objective: To address barriers assessment, communication, strategies settings, we developed a Web-based decision aid, RealRisks, that aims improve preference-based decision-making for prevention,...
In a 3-arm presurgical trial, four-six weeks exemestane 25 mg three times/week (TIW) was non-inferior to mg/day (QD) in suppressing circulating estradiol postmenopausal women with ER-positive breast cancer. Since obesity may decrease efficacy, we analyzed changes sex steroids, adipokines, Ki-67, and drug levels relation obesity. Postmenopausal early-stage cancer were randomized either QD (n = 57), TIW or mg/week (QW, n 62) for 4-6 before surgery. Serum tissue pre- post-treatment biomarkers...
Abstract Agents that can reduce the incidence of hormone receptor negative breast cancer are currently lacking. Rexinoids such as bexarotene significantly reduced mammary tumor development in preclinical mouse models. Oral BRCA mutation carriers decreased cyclin D1 cells, suggesting biological activity on tissue. This study evaluated topical 1% gel applied to one unaffected women at high risk for 4 weeks assess safety and toxicity. Secondary objectives included assessment concentrations...
Abstract Exemestane is an effective drug to reduce breast cancer risk reaching overall 65% reduction in the placebo–controlled phase III MAP.3 trial. To improve its acceptability primary prevention programs, we are seeking minimal dose. In a 3-arm presurgical trial of 4-6 weeks before surgery 180 postmenopausal women with ER-positive cancer, investigated activity alternative exemestane schedules: 25 mg per day (QD), three times/week (TIW) or week (QW) and showed that adherent participants...
The drug's activity at the target tissue could help to define minimal effective dose promote cancer preventive therapy. Here we present exemestane and sex hormone concentrations within breast from a presurgical study of alternative schedules. Postmenopausal women candidates for surgery estrogen receptor-positive were randomly assigned 25 mg once daily (QD), 3 times/week (TIW), or per week (QW) 4-6 weeks before surgery. Drug hormones analyzed homogenized frozen using QTRAP 6500+ LC-MS/MS...
519 Background: Successful therapeutic cancer prevention requires definition of the minimal effective dose proposed agent. Aromatase inhibitors substantially decreased breast incidence in high risk postmenopausal women phase III trials but their clinical use and adherence adjuvant setting is limited by adverse events. We conducted a randomized presurgical IIb trial to evaluate two alternative doses exemestane. Methods: multi-center, pre-surgical, double-blind, 3-arm, non-inferiority study...
Abstract Background: Mammographic density (MD) represents one of the strongest predictors breast cancer risk. Tamoxifen, a selective estrogen receptor modulator (SERM) and proven chemopreventive agent, causes reductions in MD which correlate with subsequent Current methods for measuring MD, such as Cumulus technique, are labor intensive not fully automated, limits utility clinical setting. Breast MRI is being used increasing frequency high-risk women screening yields 3-dimensional views...
Abstract Background: The pathologic complete response (pCR) rate in inflammatory breast cancer (IBC) patients is worse than non-IBC patients; new drug combinations are warranted to improve pCR rates across all IBC molecular subtypes. Based on our preclinical data, we added neratinib standard neoadjuvant chemotherapy both HER2+ (synergy) and HER2-/hormone receptor (HR)+ (high frequency of ERBB2 mut) untreated IBC, as a single-center, non-randomized phase I/II trial. Patients Method: This...
<div>Abstract<p>Agents that can reduce the incidence of hormone receptor negative breast cancer are currently lacking. Rexinoids such as bexarotene significantly reduced mammary tumor development in preclinical mouse models. Oral BRCA mutation carriers decreased cyclin D1 cells, suggesting biological activity on tissue. This study evaluated topical 1% gel applied to one unaffected women at high risk for 4 weeks assess safety and toxicity. Secondary objectives included assessment...
<div>Abstract<p>Agents that can reduce the incidence of hormone receptor negative breast cancer are currently lacking. Rexinoids such as bexarotene significantly reduced mammary tumor development in preclinical mouse models. Oral BRCA mutation carriers decreased cyclin D1 cells, suggesting biological activity on tissue. This study evaluated topical 1% gel applied to one unaffected women at high risk for 4 weeks assess safety and toxicity. Secondary objectives included assessment...
e13563 Background: There have been significant advances in the systemic treatment of breast cancer over past decade. Identifying factors associated with disparities receipt chemotherapy may improve mortality. The Texas Cancer Registry (TCR) is a population based registry cases which collects data on whether was recommended by treating physician and received patient. objective this study to assess demographic, clinical, geographical lack (RRC) its association Methods: TCR used identify women...
Abstract Background: Breast cancer prevention with anti-estrogens, including tamoxifen, raloxifene, and exemestane, has been shown to reduce the incidence of hormone receptor-positive breast cancer. However, agents that can receptor negative are currently lacking. Rexinoids such as bexarotene vitamin A analogues have be involved in cell differentiation, growth, apoptosis. In preclinical mouse models develop ER-negative cancers, showed a significant reduction mammary tumor development. Oral...